CHEP PLUS
Informing Through Evidence, Transforming Through Engagement.
Accreditation
This Group Learning program has been reviewed by the College of Family Physicians of Canada and certified for 6 Mainpro+ credits per 2-hour session. For physicians to receive the full credits, the post-session practice reflection survey must be completed 6 weeks after the session.
Note: Final certification is granted upon ethical review and approval of the session application
that must be submitted at least 10 days in advance of the session date.
All content is developed independently with a scientific committee to ensure the integrity of the programs to the best practices outlined in the 2018 Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care. Some modules have been recently updated to reflect new 2021 practice recommendations from our guideline partners.
​
Modules are theory informed and based on adult education and learning principles.
Learn more about the Theory and Adult Education Principles for CHEP+ Programs
​
​
MODULE TOPICS
​
CHEP Module 1 Cliff: Management of CHF and Hypertension and Atrial Fibrillation, including Prevention of Heart Failure and Atrial Fibrillation
Upon completion of this case study, participants should be able to:
• Apply the Hypertension Canada clinical practice guidelines for the management of hypertension in association with heart failure
• Explain the relationship between hypertension and heart failure, and in relation to a specific case
• Explain the relationship between hypertension and atrial fibrillation, and in relation to a specific case
CHEP Module 2 Pam: Global Cardiovascular Risk Assessment and Risk Reduction Women with Hypertension
Upon completion of this activity, participants should be able to:
• Do a critical appraisal of CV risk assessment
• Evaluate indications and limitations of CV risk stratification
• Calculate vascular age; discuss how vascular age assessment can help in CV risk reduction
• Formulate a management plan using the Hypertension Canada recommendations
CHEP Module 3 Lavani: Hypertension, Lifestyle and Sodium
Upon completion of this case study, participants should be able to:
• Apply the Hypertension Canada recommendations for the management of hypertension in association with sodium and lifestyle
• Explain the relationship between hypertension and sodium, how to prevent and manage hypertension with lifestyle modifications, and a multi-pronged approach
• Recognize high sodium content food items and lower sodium options
​
CHEP Module 4 JD: Management of Patients with Diabetes and Hypertension
Upon completion of this case study, participants should be able to:
• Plan the investigation of patients with hypertension and diabetes including evaluation for nephropathy
• Assess the cardiovascular and renal risk associated with diabetes and hypertension
• Demonstrate knowledge of the blood pressure target in people with hypertension living with diabetes
CHEP Module 5 Gerald: Management of Hypertension in Non-diabetes Patients with Chronic Kidney Disease
Upon completion of this activity, participants will be able to:
• State the new BP target for patients with non-DM CKD and understand the rationale for this change
• Identify the risk for developing CKD from HTN
• Understand and manage the increases in risk for cardiovascular outcomes in patients with non-DM CKD and hypertension
CHEP Module 6 Mariam: Blood Pressure Measurement Diagnosis and Follow-Up of Hypertension
Upon completion of this case study, participants should be able to:
• To describe the new Hypertension Canada recommendations and algorithm for the diagnosis of hypertension
• To outline the rationale for and the methods for using automated office blood pressure measurements.
• Define White Coat Hypertension, Masked Hypertension, and Masked Uncontrolled Hypertension (MUCH)
• To describe tools for helping learners acquire and teach the knowledge and skills for blood pressure measurement.
CHEP Module 8 Chi: Hypertension and Single Pill Combination Therapy
Upon completion of this activity, participants should be able to:
• Review the new Hypertension Canada recommendations for the use of single pill combinations in the treatment of hypertension
• Outline the rationale and background evidence for using single pill combination therapy as initial and ongoing therapy in the treatment of hypertension
• Describe a method for introducing a single pill combination as the initial treatment of hypertension to maximize effectiveness and minimize side effects
C-CHANGE Module 1 Tom: Management of Patients with Diabetes and Hypertension 1
Upon completion of this case study, participants should be able to:
• Formulate a multifaceted approach to reduce CV risk
• Formulate a treatment plan to achieve blood pressure control for patients with diabetes and hypertension using the clinical practice guidelines
• Assess the specific need in patients with diabetes for the use of RAAS blockers and antihyperglycemic agents with demonstrated CV and/or renal benefit to reduce cardiovascular and renal events
C-CHANGE Module 2 Jane: Global Cardiovascular Risk Assessment and Reduction in Women
Upon completion of this activity, participants should be able to:
• Identify recommendations for multiple comorbidities from the C-CHANGE guidelines
• Implement recommendations for multiple comorbidities in a single patient
• Use the C-CHANGE recommendations to help manage female patients with multiple CV risk factors
C-CHANGE Module 3 John: Hypertension and Stroke Prevention and Management
Upon completion of this case study, participants should be able to:
• Plan to assess and screen patients’ blood pressure at all appropriate visits.
• Discuss modifiable cardiovascular risk factors with patients.
• Discuss blood pressure targets and need for anticoagulation/anti-platelet therapy in people who have just suffered a stroke.
C-CHANGE Module 4 Martin: How C-CHANGE can Help Management of the multi co-morbidity patient
Upon completion of this activity, participants will be able to:
• Identify recommendations for multiple morbidities from the C-CHANGE guidelines
• Implement recommendations for multiple morbidities in a single patient
• Use the C-CHANGE recommendations to help keep the elderly living at home longer and healthier
C-CHANGE Module 5 Donald: Cardiovascular Management of Patients with Chronic Kidney Disease
Upon completion of this activity, participants should be able to:
• Identify a patient with chronic kidney disease.
• Formulate a treatment plan for cardiovascular risk reduction using the C-CHANGE guidelines including BP control and lipid management.
• Communicate and initiate the treatment plan to reduce cardiovascular risk in patients with chronic kidney disease
C-CHANGE Module 6 Joe: CV Risk Reduction in Diabetes (SGLT2 inhibitors/GLP1-RA receptor agonists in patients with DM and ASCVD)
Upon completion of this case study, participants should be able to:
• Describe the patient who should be treated with an SGLT2i or GLP-1 RA
• Explain the rationale for this treatment and the potential benefits
• Describe the steps for initiating and monitoring therapy for patients with diabetes
C-CHANGE Module 7 Emily: Anticoagulation in Nonvalvular Atrial Fibrillation in Patients with Renal Disease
Upon completion of this activity, participants should be able to:
• Describe the rational for anticoagulation of non-valvular atrial fibrillation
• Describe the effect on outcomes of non-valvular atrial fibrillation with CKD
• Describe the management of patients with CKD and non-valvular atrial fibrillation
C-CHANGE Module 8 Arnalda: ARNI in Reduced Ejection Fraction Heart Failure (HFrEF)
Upon completion of this activity, participants should be able to:
• Describe the epidemiology and pathophysiology of reduced ejection fraction heart failure (HFrEF) and preserved ejection fraction heart failure (HFpEF)
• Describe the current management of HFrEF
• Describe the evidence for ARNI in HFrEF
• Apply the clinical practice guideline for ARNI in HFrEF
C-CHANGE Module 10 Joan: Renal Protection in Patients with Diabetes and Advanced Nephropathy
Upon completion of this activity, participants should be able to:
• Describe advanced diabetic nephropathy and its consequences
• Explain the rationale for the management of advanced nephropathy and the potential benefits
• Describe how advanced nephropathy might be prevented
(FRENCH VERSION)
C-CHANGE Module 10 Joan: Protection Rénale Chez Les Patients Atteints de Diabète et de Nephropathie Avancée
Objectifs d’apprentissage
• Décrire la néphropathie diabétique avancée et ses conséquences
• Expliquer les motifs de la prise en charge de la néphropathie avancée et les bienfaits potentiels
• Décrire la façon dont la néphropathie avancée peut être prévenue
​
​
​